New hope for advanced cancer patients: CS01 drug trial begins
NCT ID NCT07461181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called CS01 in about 10 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study is currently active but not recruiting new participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Immune-Boosting pill make immunotherapy work better against Hard-to-Treat tumors?
- Can a new drug shrink Hard-to-Treat cancers? an early trial seeks answers
- Can a new drug ASP388B take on advanced solid tumors?
- Can a new infusion drug tame advanced solid tumors?
- New antibody drug takes aim at Hard-to-Treat cancers
- New cancer pill enters first human tests for advanced solid tumors